President and Chief Executive Officer
Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Keryx Biopharmaceuticals and The American Cancer Society of Eastern New England.
Executive Vice President, General Counsel and Secretary
Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.
Executive Director, Human Resources
Audrey Bergan joined ImmunoGen in 2014, bringing more than 20 years of experience in human resources and talent acquisition strategy. Responsible for leading ImmunoGen’s Human Resources team, she has been instrumental in defining and evolving the company’s culture and HR infrastructure. Prior to her current leadership role, Mrs. Bergan was responsible for building a Talent Acquisition function at ImmunoGen. Prior to ImmunoGen, she spent seven years at Biogen where she held multiple talent acquisition leadership roles. Mrs. Bergan holds a MS in Human Resourcing from Northeastern University, and a BS in Psychology from UMASS Amherst.
Vice President, Chief Medical Officer
Anna Berkenblit, MD, MMsC
Dr. Berkenblit joined ImmunoGen in 2015 and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates.She has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior to H3 Biomedicine, she was VP, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials.
Prior to AVEO, Dr. Berkenblit held positions of increasing responsibility at
Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. Dr. Berkenblit earned an MD degree from Harvard Medical School, and an MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women’s Hospital, then went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center where she stayed on staff to focus on clinical research in GYN and GI malignancies. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, prior to transitioning to industry.
Executive Vice President and Chief Scientific Officer
Richard J. Gregory, PhD
Dr. Gregory joined ImmunoGen in 2015 bringing over twenty-five years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. In 2003, he was appointed the head of research at Genzyme, with responsibility for early research – from discovery to development – for all Genzyme therapeutic areas, including an ADC initiative. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Gregory was appointed head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval. Richard received his doctorate in biochemistry from the University of Massachusetts at Amherst, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology.
Executive Vice President and Chief Financial Officer
David B. Johnston
David Johnston joined ImmunoGen in December 2013 as EVP and CFO bringing to ImmunoGen more than 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, as well as extensive experience in corporate planning. Prior to joining ImmunoGen, Mr. Johnston was chief financial officer at AVEO Pharmaceuticals Inc. Prior to joining AVEO in 2007, he was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corporation and, before that, the VP Finance and CFO of Genzyme Biosurgery. Prior to joining Genzyme in 1998, Mr. Johnston held financial, planning and analysis positions of increasing responsibility at several major corporations. He holds a BS degree from Washington and Lee University and an MBA from the University of Michigan.
Executive Vice President, Chief Business Officer
Blaine McKee, PhD
Dr. McKee has 25 years of experience in building biotechnology companies and has extensive strategic, transactional, and market access expertise. He joined ImmunoGen from Shire plc, where he served as Head of Corporate Development, leading corporate strategy, M&A, due diligence, commercial assessment, and alliance management functions. Prior to joining Shire, Dr. McKee was Executive Vice President and Chief Business Officer at 480 Biomedical, a venture capital-backed medical device company. Before joining 480 Biomedical, he held a number of positions of increasing responsibility at Genzyme over a 15-year tenure, most recently serving as Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions.
Dr. McKee currently serves on the Board of BioStage, Inc. and served for many years on the Board of the New York Pharma Forum. He received a Bachelor of Science in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.
Vice President, Technical Operations
Thomas Ryll, PhD
Dr. Ryll joined ImmunoGen in August 2015 as Vice President of Process and Analytical Development and took on leadership of Technical Operations in 2017. With 24 years of experience in bioprocessing, throughout his career he served in roles of increasing responsibility in process development, scale-up, manufacturing support, and development of scientific talent at Genentech, Abgenix, Tanox, and Biogen. Dr. Ryll obtained his doctorate in Biochemistry and Biotechnology from the Technical University of Braunschweig in Germany, developing cell culture based production processes for recombinant proteins and associated control approaches.
Senior Vice President, Regulatory Affairs and Quality
Theresa Wingrove, PhD
Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company’s combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.